GELESIS HOLDINGS, INC.
Closed (deSPAC)Profile in progress
- What it is
- Gelesis Holdings Inc
- What it’s doing now
- Merging with CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (CPSR) — closed (despac).
- What you should know
- The deal carries a $105M minimum-cash condition — heavy redemptions can break it.
The business, per its filings
SEC primaryGelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a consumer-centered biotherapeutics company and the maker of Plenity®, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks. They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. For more information, visit gelesis.com , or connect with us on Twitter @GelesisInc. Plenity® is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m², when used in conjunction with diet and exercise. Important Safety Information about Plenity ● Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity. ● To avoid impact on the absorption of medications: o For all medications that should be taken with food, take them after starting a meal. o For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician. ● The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. ● Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using
What the company says about itself
Web research — not auditedGelesis develops GI & Metabolic based biomimetic therapies designed to support physiology and long-term health outcomes. Their proprietary OHS platform is a superabsorbent hydrogel technology that works locally in the GI tract. The company's primary product is Plenity®, an orally administered, non-stimulant, non-systemic aid to weight management indicated for adults with a BMI of 25 to 40 kg/m².
- Markets:
- Medical Devices | Weight Management | Metabolic Health
- Products:
- Plenity | OHS platform
[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "At Closing, Gelesis is expected to have a pro forma implied market value of approximately $1.3 billion to support full commercial launch of ..." [https://investors.puretechhealth.com/node/9681/pdf]
Source: https://www.gelesis.com/en/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
GELESIS HOLDINGS, INC. is merging with CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (CPSR) currently marked Closed (deSPAC).
| Headline equity value | — |
| Minimum cash to close | $105M |
Structure per SEC accession(s) 0001104659-22-002447, 0000950170-23-027586. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is GELESIS HOLDINGS, INC. going public?
GELESIS HOLDINGS, INC. has an approved merger with the SPAC CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (CPSR). Deal status: Closed (deSPAC).
Does GELESIS HOLDINGS, INC. have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.